Enanta Pharmaceuticals | ENTA - Bienes





Bienes Cambio Fecha
AbbVie USD 133.96B 62M 2025-12
Amgen USD 92.5B 1.92B 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 1.6B 218.89M 2025-12
AstraZeneca USD 114.02B 59M 2026-03
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Biogen USD 29.48B 43.6M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Immunic USD 24.05M 16.65M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Insmed USD 2.26B 96.18M 2025-12
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
J&J USD 200.89B 1.68B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Ligand Pharmaceuticals USD 1.56B 83.86M 2025-12
Merck USD 128.68B 8.18B 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novavax USD 1.18B 3.38M 2025-12
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.9B 255.07M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03